Polypill cuts cardiovascular event risk in seniors with recent MI
Aug 30, 2022
A polypill comprising aspirin, ramipril and atorvastatin is effective for secondary prevention of cardiovascular disease in older adults.
Extreme heat projected to cause more excess cardiovascular deaths by midcentury
Oct 30, 2023
In one scenario, elderly adults are projected to have a 3.5 times greater increase in deaths compared with nonelderly adults.
Semaglutide boosts kidney outcomes with obesity + cardiovascular disease
May 28, 2024
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.
Overall cardiovascular health score less than optimal for U.S. adults
Jun 29, 2022
Significant differences in mean overall CVH scores were based on Life’s Essential 8 by sex, age and racial/ethnic group.
Ultraprocessed foods increase risk for broad range of poor health outcomes
Mar 07, 2024
The findings were seen across cardiometabolic common mental disorder and mortality outcomes.
Cannabis use linked to adverse cardiovascular outcomes
Feb 28, 2024
Proportionately lower log odds were seen for heart disease, heart attack, stroke and composite outcome for days of use between zero and 30 a month.
Sex differences examined for mechanism of migraine-stroke link
Dec 08, 2021
Sex differences in stroke pathophysiology in patients with migraine seem unrelated to the prevalence of conventional cardiovascular risk factors.
USPSTF: Do not start low-dose aspirin to prevent CVD in 60+
Apr 26, 2022
For those aged 40 to 59 years, the decision to initiate low-dose aspirin for primary prevention of CVD should be individualized.
USPSTF advises against starting aspirin in ≥60s to prevent CVD
Oct 12, 2021
The U.S. Preventive Services Task Force (USPSTF) recommends against initiating use of aspirin for the primary prevention of cardiovascular disease (CVD) for adults aged 60 years or older.